编辑“︁Rosetta@home”︁（章节）

=== 炭疽病 ===
Rosetta的另一个组件RosettaDock<ref>{{Cite journal|title=Improved side-chain modeling for protein-protein docking|url=http://doi.wiley.com/10.1110/ps.041222905|last=Wang|first=Chu|last2=Schueler-Furman|first2=Ora|date=2005-05|journal=Protein Science|issue=5|doi=10.1110/ps.041222905|volume=14|pages=1328–1339|language=en|pmc=2253276|pmid=15802647|last3=Baker|first3=David}}</ref><ref>{{Cite journal|title=Protein–Protein Docking with Simultaneous Optimization of Rigid-body Displacement and Side-chain Conformations|url=https://linkinghub.elsevier.com/retrieve/pii/S0022283603006703|last=Gray|first=Jeffrey J.|last2=Moughon|first2=Stewart|date=2003-08|journal=Journal of Molecular Biology|issue=1|doi=10.1016/S0022-2836(03)00670-3|volume=331|pages=281–299|language=en|pmid=12875852|last3=Wang|first3=Chu|last4=Schueler-Furman|first4=Ora|last5=Kuhlman|first5=Brian|last6=Rohl|first6=Carol A.|last7=Baker|first7=David|access-date=2022-05-01|archive-date=2022-03-27|archive-url=https://web.archive.org/web/20220327042616/https://linkinghub.elsevier.com/retrieve/pii/S0022283603006703}}</ref><ref name="Schueler-Furman">{{Cite journal|title=Progress in protein-protein docking: Atomic resolution predictions in the CAPRI experiment using RosettaDock with an improved treatment of side-chain flexibility|url=https://onlinelibrary.wiley.com/doi/10.1002/prot.20556|last=Schueler-Furman|first=Ora|last2=Wang|first2=Chu|date=2005-06-24|journal=Proteins: Structure, Function, and Bioinformatics|issue=2|doi=10.1002/prot.20556|volume=60|pages=187–194|language=en|pmid=15981249|last3=Baker|first3=David|access-date=2022-05-01|archive-date=2022-05-01|archive-url=https://web.archive.org/web/20220501011219/https://onlinelibrary.wiley.com/doi/10.1002/prot.20556}}</ref>与实验方法相结合，被用于构造致死因子（lethal factor，LF）、水肿因子（edema factor，EF）和保护性抗原（protective antigen，PA）等三种蛋白质的交互作用模型。这三种蛋白质构成了[[炭疽病]][[毒素]]。这个模型精确预测LF与PA之间的对接，帮助确定两种蛋白质分别有哪些[[结构域]]参与到LF-PA复合体的构造中。这项成果最终被应用到改良的炭疽病[[疫苗]]的研制。<ref>{{Cite journal|title=A model of anthrax toxin lethal factor bound to protective antigen|url=https://pnas.org/doi/full/10.1073/pnas.0508259102|last=Lacy|first=D. Borden|last2=Lin|first2=Henry C.|date=2005-11-08|journal=Proceedings of the National Academy of Sciences|issue=45|doi=10.1073/pnas.0508259102|volume=102|pages=16409–16414|language=en|issn=0027-8424|pmc=1283467|pmid=16251269|last3=Melnyk|first3=Roman A.|last4=Schueler-Furman|first4=Ora|last5=Reither|first5=Laura|last6=Cunningham|first6=Kristina|last7=Baker|first7=David|last8=Collier|first8=R. John|access-date=2022-05-01|archive-date=2022-05-02|archive-url=https://web.archive.org/web/20220502130941/https://www.pnas.org/doi/full/10.1073/pnas.0508259102}}</ref><ref>{{Cite journal|title=Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect against Bacillus anthracis Infection and Enhance Endogenous Immunity to Anthrax|url=https://journals.asm.org/doi/10.1128/IAI.00261-07|last=Albrecht|first=Mark T.|last2=Li|first2=Han|date=2007-11|journal=Infection and Immunity|issue=11|doi=10.1128/IAI.00261-07|volume=75|pages=5425–5433|language=en|issn=0019-9567|pmc=2168292|pmid=17646360|last3=Williamson|first3=E. Diane|last4=LeButt|first4=Chris S.|last5=Flick-Smith|first5=Helen C.|last6=Quinn|first6=Conrad P.|last7=Westra|first7=Hans|last8=Galloway|first8=Darrell|last9=Mateczun|first9=Alfred|access-date=2022-05-01|archive-date=2021-08-07|archive-url=https://web.archive.org/web/20210807011003/https://journals.asm.org/doi/10.1128/IAI.00261-07}}</ref>